Back to News
Market Impact: 0.2
Evogene Targets Acute GVHD With AI-Driven Drug Discovery Program
Source: Nasdaq
Healthcare & BiotechArtificial IntelligenceCompany Fundamentals
Evogene announced acute graft-versus-host disease as the target indication for an internal drug discovery program. The announcement identifies the program's intended focus but provides no development milestones, efficacy data, or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
EVGN0.20
More News
- Stocks slump, bonds leap as AI giants’ spending spooks investors
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates